TopBuildの空売り状況は、投資家がTopBuildの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

TopBuild (NYSE:BLD) 株価情報, 空売り情報

TOPBUILD CORP

TopBuild

TopBuild Corp is an installer and distributor of insulation products. Its operating segments involve the Installation and Specialty Distribution segment. The installation segment provides insulation installation services nationwide through contractor services business. Speciality Distribution segment distributes building and mechanical insulation, insulation accessories and other building product materials for the residential, commercial, and industrial end markets. The majority of revenue is earned from the installation segment. Its main customers are contractors. Other products include gutters, after-paint, garage doors, fireplaces, and fireproofing and stopping. TopBuild operates majorly in the United States.

TopBuild Corp

Blade Air Mobility, Inc. - Class A Common Stock

Blade Air Mobility Inc

Cambria Global Real Estate ETF

Ballard Power Systems, Inc. - Common Shares

Ballard Power Systems Inc

Builders FirstSource Inc

BLUE DIAMOND VENTURES INC by Blue Diamond Ventures, Inc.

Blue Diamond Ventures Inc

<ul>
<li>Orders of $1.0 billion, reflecting growth of 7% or 2% on an organic basis, driven by pump project and connectors awards</li>
<li>Revenue of more than $900 million; flat on a GAAP and organic basis, driven by strength in pumps aftermarket, connectors and rail, offset by lower aerospace demand</li>
<li>Operating margin of 16.5% and adjusted operating margin of 17.4%, impacted by unfavorable foreign currency</li>
<li>Earnings per share (EPS) of $1.29 to $1.35 and adjusted EPS of $1.43 to $1.45</li>
<li>Net cash from operating activities of $107 million to $117 million and free cash flow of $70 million to $80 million</li>
</ul>

Earnings

News

Guidance

General

ITT Released Preliminary Q1 2025 Sales Of Over $900M Vs. Consensus Of $901.06M, With Adjusted EPS $1.43-$1.45 Vs. Consensus Of $1.43

Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Hold to Hold.

Reiteration

Analyst Ratings

AMPH

Needham Reiterates Hold on Amphastar Pharmato Hold

Goldman Sachs analyst Mark Delaney downgrades Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Buy to Neutral and lowers the price target from $11 to $9.

Downgrades

Price Target

Goldman Sachs Downgrades Ford Motor to Neutral, Lowers Price Target to $9

Goldman Sachs analyst Matt Greene upgrades ArcelorMittal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MT#NYSE">MT</a>) from Neutral to Buy and raises the price target from $29 to $31.7.

Upgrades

Goldman Sachs Upgrades ArcelorMittal to Buy, Raises Price Target to $31.7

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $12 price target.

IMRX

Needham Reiterates Buy on Immuneering, Maintains $12 Price Target

B of A Securities analyst Craig Siegenthaler upgrades Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) from Neutral to Buy and maintains the price target from $65 to $65.

B of A Securities Upgrades Brookfield Asset Mgmt to Buy, Maintains Price Target to $65

<ul>
<li>Combined business to be renamed Elevra Lithium upon merger completion</li>
<li>Elevra Lithium Board of Directors Nominees named with four members from each standalone business select</li>
</ul>

Piedmont Lithium And Sayona Mining To Merge As Elevra Lithium; Board Nominees Announced

B of A Securities analyst Joshua Dennerlein initiates coverage on MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) with a Neutral rating and announces Price Target of $585.

Initiation

MSCI

B of A Securities Initiates Coverage On MSCI with Neutral Rating, Announces Price Target of $585

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Edgewise Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>)</h3>
<ul>
<li>On April 2, Edgewise Therapeutics priced an underwritten public offering of 9.94 million shares at $20.13 per share, expecting to raise approximately $200 million. The offering is set to close on April 3, pending customary conditions. The company's stock fell around 55% over the past month and has a 52-week low of $10.60.</li>
<li>RSI Value: 27.5</li>
<li>EWTX Price Action: Shares of Edgewise Therapeutics gained 8.8% to close at $12.50 on Wednesday.</li>
<li>Edge Stock Ratings: 15.43 Momentum score. </li>
</ul>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/ewtx"><img loading="lazy" decoding="async" width="493" height="173" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png" alt="" class="wp-image-865422" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59.png 493w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043318/image-59-300x105.png 300w" sizes="(max-width: 493px) 100vw, 493px" /></a></figure>
<h3 class="wp-block-heading">Genfit SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Feb. 7, HC Wainwright &amp; Co. analyst Ed Arce reiterated Genfit with a Buy rating and maintained a $13 price target. The company's stock fell around 27% over the past five days and <a href="https://www.benzinga.com/quote/GNFT">has a 52-week low</a> of $2.55.</li>
<li>RSI Value: 29.3</li>
<li>GNFT Price Action: Shares of Genfit dipped 21.4% to close at $2.64 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">GNFT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="921" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png" alt="" class="wp-image-865424" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043427/image-60-768x694.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">CAMP4 Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>)</h3>
<ul>
<li>On March 27, CalAmp reported a quarterly loss of $11.04 per share which met the analyst consensus estimate. &#8220;We are off to a strong start in 2025, building on the momentum of a successful 2024, which included advancing our Phase 1 clinical program in UCDs, establishing key research collaborations, securing important regulatory designations, and completing our initial public offering,&#8221; said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. The company's stock fell around 49% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CAMP">low of $0.39.</a></li>
<li>RSI Value: 23.1</li>
<li>CAMP Price Action: Shares of CAMP4 Therapeutics dipped 7.4% to close at $2.14 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410">CAMP shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0410"><img loading="lazy" decoding="async" width="886" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png" alt="" class="wp-image-865425" style="width:416px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61.png 886w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/10043516/image-61-768x716.png 768w" sizes="(max-width: 886px) 100vw, 886px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44710375/top-2-materials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Materials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

CAMP

EWTX

GNFT

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

The Buckle, &nbsp;comparable store net sales, for stores open at least one year, for the 5-week period ended April 5, 2025 increased 3.7 percent from comparable store net sales for the 5-week period ended April 6, 2024. Net sales for the 5-week fiscal month ended April 5, 2025 increased 4.5 percent to $109.1 million from net sales of $104.3 million for the prior year 5-week fiscal month ended April 6, 2024.

Buckle Reports 4.5% YoY Increase In March Net Sales To $109.1M; Comparable Store Sales Rise 3.7%

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) with a Buy and maintains $9 price target.

MBOT

HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $9 Price Target

B of A Securities analyst Craig Siegenthaler downgrades Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) from Buy to Neutral and lowers the price target from $260 to $227.

CBOE

B of A Securities Downgrades Cboe Global Markets to Neutral, Lowers Price Target to $227

B of A Securities analyst Federico Merendi initiates coverage on Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) with a Buy rating and announces Price Target of $53.

PHIN

B of A Securities Initiates Coverage On Phinia with Buy Rating, Announces Price Target of $53

Needham analyst Ryan MacDonald reiterates Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) with a Buy and maintains $42 price target.

DCBO

Needham Reiterates Buy on Docebo, Maintains $42 Price Target

CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) reported quarterly earnings of $0.58 per share which missed the analyst consensus estimate of $0.68 by 14.71 percent. This is a 81.25 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $6.00 billion which beat the analyst consensus estimate of $5.96 billion by 0.67 percent. This is a 6.68 percent increase over sales of $5.63 billion the same period last year.

Earnings Beats

Earnings Misses

CarMax Q4 2025 GAAP EPS $0.58 Misses $0.68 Estimate, Sales $6.00B Beat $5.96B Estimate

B of A Securities analyst Caio Ribeiro upgrades Vale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>) from Neutral to Buy and raises the price target from $11 to $11.5.

VALE

B of A Securities Upgrades Vale to Buy, Raises Price Target to $11.5

B of A Securities analyst Christopher Nardone upgrades Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) from Neutral to Buy and raises the price target from $17 to $20.

LEVI

B of A Securities Upgrades Levi Strauss to Buy, Raises Price Target to $20

HC Wainwright &amp; Co. analyst Joseph Pantginis downgrades Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) from Buy to Neutral and maintains the price target from $16 to $16.

Tempest Therapeutics, Inc. - Common Stock

TPST

HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16

Needham analyst Scott Berg reiterates Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) with a Buy and maintains $28 price target.

THRY

Needham Reiterates Buy on Thryv Holdings, Maintains $28 Price Target

<a href="https://x.com/vonderleyen/status/1910278392349327628" title="https://x.com/vonderleyen/status/1910278392349327628">https://x.com/vonderleyen/status/1910278392349327628</a>

Macro Economic Events

Economics

EU's Ursula von der Leyen on X Said "We took note of the announcement by President Trump. We want to give negotiations a chance. While finalising the adoption of the EU countermeasures that saw strong support from our Member States, we will put them on hold for 90 days."

Comments

TopBuild

空売り

TopBuild (NYSE:BLD) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル